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Summary: The novel Trypanosoma brucei gambiense inhibition ELISA (g-iELISA) is a high-throughput 
diagnostic applicable in regional laboratories for monitoring g-HAT elimination. On plasma samples, 
sensitivity was 98.0% and specificity 99.5%, while on dried blood spots sensitivity was 92.6% and 
specificity 100%.  
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Abstract 
Background. The World Health Organization targeted Trypanosoma brucei gambiense human African 
trypanosomiasis (gHAT) for elimination as a public health problem and for elimination of 
transmission. To measure gHAT elimination success with prevalences close to zero, highly specific 
diagnostics are necessary. Such a test exists in the form of an antibody-mediated complement lysis 
test, the trypanolysis test, but biosafety issues and technological requirements prevent its large-
scale use. We developed an inhibition ELISA with high specificity and sensitivity that is applicable in 
regional laboratories in gHAT endemic countries. 
Methods. The T. b. gambiense inhibition ELISA (g-iELISA) is based on the principle that binding of 
monoclonal antibodies to specific epitopes of T. b. gambiense surface glycoproteins can be inhibited 
by circulating antibodies of gHAT patients directed against the same epitopes. Using trypanolysis as 
reference test, the diagnostic accuracy of the g-iELISA was evaluated on plasma samples from 739 
gHAT patients and 619 endemic controls and on dried blood spots prepared with plasma of 95 gHAT 
and 37 endemic controls.  
Results. Overall sensitivity and specificity on plasma were respectively 98.0% (95% CI 96.7 - 98.9) and 
99.5% (95% CI 98.6-99.9). With dried blood spots, sensitivity was 92.6% (95% CI 85.4 - 97.0), and 
specificity was 100% (95% CI 90.5 - 100.0). The g-iELISA is stable for at least 8 months when stored at 
2-8°C. 
Conclusion. The g-iELISA might largely replace trypanolysis for monitoring gHAT elimination and for 
post-elimination surveillance. The g-iELISA kit is available for evaluation in reference laboratories in 
endemic countries. 
Keywords: Trypanosoma brucei gambiense; elimination; ELISA; diagnosis 
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Introduction 
Human African trypanosomiasis (HAT) is an infectious disease caused by the protozoan Trypanosoma 
brucei (T.b.) [1]. Transmission occurs via infected tsetse (Glossina sp.), which confines the disease to 
sub-Saharan Africa [2]. Two geographically separated sub-species are responsible for the disease in 
humans: T.b. gambiense type I in West and Central Africa and T.b. rhodesiense in Eastern Africa [2]. 
Some atypical human infections are due to another trypanosome taxon, called T.b. gambiense type II 
but are very rare and not considered here [3]. Both gambiense-HAT (gHAT) and rhodesiense-HAT 
(rHAT) are neglected tropical diseases, however, despite this improved control tools for gHAT 
recently appeared, like rapid diagnostic tests (RDTs) for diagnosis, new drugs including nifurtimox-
eflornithine combination therapy (NECT) and fexinidazole for treatment, and tiny targets for vector 
control. Sustained control activities in most affected countries have reduced annual incidence to a 
point where elimination of gHAT as a public health problem (<2,000 reported cases reported 
annually and 90% reduction of the area at risk reporting ≥ 1 case/10,000 people/year), seems 
feasible, and elimination of transmission (EOT, zero human cases of gHAT) is now the new target [4-
6]. However, as long as tsetse populations subsist, gHAT may reappear in foci that are considered 
eliminated. Re-emergence of the disease may be caused by i) an animal reservoir, although the 
epidemiological role of animals is still under debate or ii) a human reservoir in the form of patients 
that are not picked up by active or passive surveys or asymptomatic carriers that harbour the 
infection for years or decades without developing the disease [7-9].  
Measuring EOT of gHAT poses new challenges for diagnosis, especially as this infection often persists 
at extremely low levels. Likewise, there is a threat of re-emergence or re-invasion from another area 
with ongoing transmission. In epidemic and endemic situations where the goal is to drastically and 
rapidly reduce incidence, diagnostics should be highly sensitive which usually compromises their 
specificity but results in a high negative predictive value (NPV) following the formula NPV = 
                          
                                                     
. On the other hand, when prevalence is near 
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zero, it is important to use diagnostics with very high specificity to avoid any false-positive results 
that may trigger unnecessary alarm and ensuing actions. High specificity results in high positive 
predictive values (PPV) following the formula PPV = 
                       
                                                      
. 
Parasitological diagnosis of gHAT, based on microscopic detection of the parasite in blood, lymph or 
cerebrospinal fluid, is highly specific, but moderately sensitive [2]. For this reason, field applicable 
serological tests have been introduced since the 1970s [10]. They have been instrumental in the 
control of gHAT but are ineffective for rHAT. The card agglutination test for trypanosomiasis (CATT), 
of which several million are used each year, is particularly useful for large-scale screening of 
populations at risk. The test's sensitivity and specificity are estimated at 91.2% and 97.4%, 
respectively [11]. RDTs have been available since 2013. A comparative study on archived specimens 
from West Africa reported sensitivities of 98.5% for the gambiense Sero K-SeT and 99.6% for the SD 
Bioline HAT; specificities were much lower, 98.6% and 97.1% respectively [12]. With these 
characteristics, CATT or RDTs cannot be recommended for post-elimination monitoring of gHAT – 
even in current screening programmes a single RDT or CATT positive test is not alone considered 
sufficient for administration of treatment – and confirmation by microscopy is required. Diagnostics 
for an endgame setting must be increasingly specific, otherwise there will overwhelmingly be more 
false positives than true positives [13, 14]. An alternative could be the variant-specific trypanolysis 
test (TL) [15]. This antibody-mediated complement lysis test combines high specificity and high 
analytical sensitivity and is used to confirm the presence of gambiense-specific antibodies in CATT or 
RDT positive individuals but in which the parasite cannot be demonstrated by microscopy or 
molecular tests [16]. 
The TL test is recognised by the World Health Organization (WHO) as the reference test for contact 
with T.b. gambiense and, as such, is performed at the WHO Collaborating Centers on HAT (Institute 
of Tropical Medicine Antwerp, Belgium, and Institut National de Recherche Biomédicale, Democratic 
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Republic of the Congo [DRC]) and in Centre International de Recherche-Développement sur l'Elevage 
en zone Subhumide, Burkina Faso. The test is applicable in laboratory conditions on serum, plasma 
and dried blood spots (DBS) [17]. Its specificity is due to the fact that on intact bloodstream 
trypomastigotes of T. brucei, only the variable antigen type (VAT)-specific epitopes of the variant 
surface glycoprotein (VSG) coat are accessible to conventional antibodies (IgM and IgG). VAT-specific 
antibodies in a test specimen will opsonise the trypanosomes that are subsequently lysed by 
antibody-mediated complement lysis. As most gHAT patients have antibodies against the VATs Lille 
Trypanosome antigen types 1.3 and/or 1.5 (LiTat 1.3, LiTat 1.5), TL is carried out with both variants 
[15]. The primary disadvantage of TL is that it requires in vivo propagation of highly-virulent T.b. 
gambiense clones, which puts the laboratory personnel under biohazard risk. Secondary 
disadvantages are the low throughput (400 samples/week) and high cost (5-7 €/test).  
We here describe the development of an inhibition ELISA (iELISA) with similar diagnostic accuracy 
but fewer disadvantages than TL. In the Trypanosoma brucei gambiense-iELISA (g-iELISA), the 
binding of monoclonal antibodies (mAbs) to VAT-specific epitopes on the VSGs of T.b. gambiense 
variants LiTat 1.3 and LiTat 1.5, is inhibited by binding of antibodies in the blood of gHAT patients 
directed to the same epitopes. 
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Materials and Methods 
We first established a Target Product Profile (TPP) describing the intended use and test 
characteristics (Supplementary material 1). The profile defined for the g-iELISA is that of a tool to 
monitor the progress towards gHAT elimination and to assess the presence/absence of T.b. 
gambiense in the human population of a focus where gHAT transmission is thought to have stopped. 
The test must be applicable in national and regional laboratories in sub-Saharan African countries 
affected by gHAT. Serum, plasma or DBS, collected in local health facilities or through population 
surveys, are sent to the nearest laboratory able to run the g-iELISA. Sensitivity must be at a 
minimum >90% and optimistically ≥ 95% and specificity must be at a minimum ≥99.5% and 
optimistically 100%. g-iELISA stability should be at a minimum 24 months at 4°C and optimistically 24 
months at 30°C. The g-iELISA will be commercialised as in vitro diagnostic device (IVD) submitted to 
the European Directive 98/79/EC (IVDD 98/79/EC). 
For development of the g-iELISA and to define a cut-off value, we used plasma samples collected 
during a previous study conducted in the DRC [18].  
Purified VSGs were produced following Büscher and co-workers with some modifications [19] 
(Supplementary material 2). Reactivity of the VSGs was assessed in indirect ELISA by testing two-fold 
dilutions, ranging from 4 to 0.125 µg/mL, with both variant-specific mAbs described below. 
Mouse mAbs against VSG LiTat 1.3 (clone 7B1D7) and LiTat 1.5 (clone 1A11G10) were generated 
using standard protocols at Icosagen Cell Factory (Tartumaa, Estonia). 
VAT-specific chicken IgY were produced at the University of KwaZulu-Natal. IgY antibodies were 
affinity purified on VSG LiTat 1.3 and LiTat 1.5 columns and (cross)-reactivity was verified in ELISA 
(Supplementary material 3). 
The Research Use Only (RUO) prototype g-iELISA was developed at Advanced Practical Diagnostics 
(Supplementary material 4).  
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Diagnostic accuracy of this RUO g-iELISA (index test) on plasma was assessed on 1358 samples from 
gHAT patients and controls from the WHO Human African Trypanosomiasis Specimen Bank and 
originating from DRC, Guinea, Chad and Uganda [20]. Controls were individuals living in endemic 
areas with negative serology (CATT) and parasitology for gHAT, and without previous gHAT infection. 
To assess the diagnostic accuracy of the g-iELISA on DBS, samples were prepared with healthy donor 
blood of which plasma was replaced by plasma of 95 TL-positive gHAT patients and 37 endemic 
controls [18, 21] (Supplementary material 5). 
Trypanolysis was used as reference test. All plasma samples were tested in TL with two VATs of T.b. 
gambiense type I, i.e. LiTat 1.3 and LiTat 1.5, according to [15] with a cut-off of 30%.  
 
Results 
Cut-off value 
To define a percent inhibition cut-off value, 87 TL-positive and 275 TL-negative samples from DRC 
were tested. Combining the results obtained with each VSG antigen separately (Figure 1), the 
sensitivity and specificity were calculated at varying % inhibition cut-off values. The Youden index 
(sensitivity + specificity - 1) was highest between 24% and 37% inhibition cut-off value (0.977 and 
0.966 respectively). Percent inhibition values ranged from -52.5% to 95.3% in the test with LiTat 1.3 
VSG and from -19.6% to 98.3% in the test with LiTat 1.5 VSG. Despite all attempts to avoid the 
negative percent inhibition often observed with TL-negative samples and with the LiTat 1.3 VSG, we 
were not able to overcome this unexpected phenomenon that, on the other hand, did not hinder to 
score the final result as positive or negative.  
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Results on plasma samples 
All 1358 plasma samples were tested in TL against T.b. gambiense LiTat 1.3 and LiTat 1.5. With TL as 
the reference test and using 35% inhibition as cut-off in the index test, the overall diagnostic 
accuracy of the g-iELISA is 99.5% with a 95% confidence interval (CI) of 99.0% to 99.8 (computed 
using the exact Clopper-Pearson method), assuming a 0.05% prevalence as reported for active 
screening [4]. The sensitivity is 98.0%, and the specificity is 99.5% (Table 1). Thus, values for 
sensitivity and specificity are above the values set in the TPP, ≥ 95% (optimistic) for sensitivity and 
(minimum) > 99.5% for specificity. This is also the case when stratifying the results per country, 
except for DRC where observed specificity was slightly lower (99.47%) than the minimum value 
proposed in the TPP (99.5%). 
Results on DBS 
With TL as reference test and 35% inhibition cut-off in the index test, the diagnostic accuracy of the 
g-iELISA on plasma samples is 100.0% (95% CI 97.2-100.0). The sensitivity is 94.7%, which is 
somewhat lower than the optimistic value but well above the minimum value (> 90.0%) set in the 
TPP; the specificity is 100% (Table 2). With 20% inhibition cut-off, the diagnostic accuracy on DBS is 
100.0% (97.2% to 100.0) with a sensitivity of 92.6% and a specificity of 100.0% (Table 2). Compared 
to the sensitivity obtained with the corresponding plasma samples, testing DBS induced a small loss 
in sensitivity (2.1%) but still above the minimum value set in the TPP. Agreement between results 
obtained in g-iELISA with plasma and DBS is almost perfect (Cohen's kappa k = 0.897, 95% CI: 0.73-
1.067) [22].  
Precision 
Repeatability, expressed as coefficient of variation (%CV) of 20 tests on the same sample in the same 
run, varied between 1.6% with antigen LiTat 1.5 and 5.8% with antigen LiTat 1.3 (Table 3). 
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Reproducibility, expressed as the %CV on 6 samples tested in 4 different runs, varied between 1.7% 
with LiTat 1.5 and 18.9% with LiTat 1.3 (Table 4). 
Stability testing 
Accelerated stability testing, performed according to ISO 23640, revealed considerable variation in 
optical density (O.D.) values obtained with samples and controls in the test with LiTat 1.3 antigen, in 
contrast to LiTat 1.5 antigen. The % inhibition remained stable over time for all storage conditions 
except for the TL-negative samples tested with LiTat 1.3 antigen (Figure 2). 
So far, real-time stability testing of g-iELISA kits stored at the storage temperature prescribed in the 
IFU (2-8°C), showed that the kits remain stable after 8 months storage at that temperature. Stability 
will further be followed up to 24 months. 
 
Discussion and conclusion 
This study was undertaken to develop a high-throughput surveillance test for monitoring the EOT of 
T.b. gambiense and to assess its sustained absence or re-emergence in gHAT foci in the post-
elimination phase. Since the test will be deployed in situations where infection rates are very low or 
zero, it should have a high positive predictive value and therefore a very high specificity to avoid 
raising the alarm unnecessarily [23]. We opted for an ELISA since this test format is cheap and can be 
implemented in national and regional laboratories in sub-Saharan Africa, in contrast to TL, which is 
the WHO recommended reference test for anti-T.b. gambiense antibodies in humans, but that is 
performed in only three laboratories world-wide. At least three times more samples can be tested 
simultaneously in g-iELISA while for TL the limit is 400 samples per week. Aiming at high specificity of 
the new test, we designed it as an inhibition ELISA based on the recognition of two specific epitopes 
by two mAbs, each conjugated with horseradish peroxidase; thus i) avoiding reaction of test sample 
antibodies with other, less specific epitopes present on native VSGs and ii) obviating the need for 
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host-specific antibody conjugates when testing other host species that may harbour T.b. gambiense 
infections, such as domestic animals. As positive controls, we selected chicken antibodies (IgY) over 
mammalian antibodies since they can be produced in a less invasive, more cost-effective way and in 
much larger amounts. Purified IgYs are stable up to 60 °C [24] and remain reactive following storage 
at 4 °C for several years (Coetzer, unpublished observation).  
The g-iELISA makes use of a combination of native T.b. gambiense antigens that are also used in 
other serodiagnostic tests for gHAT, like the RDTs HAT Sero-K-SeT and SD Bioline HAT [25, 26], latex 
agglutination [27] and other ELISAs [28, 29]. None of these tests had a specificity higher than the 
minimum of 99.5% proposed in the TPP. For example, an ELISA with a mixture of VSGs LiTat 1.3, 
LiTat 1.5 and LiTat 1.6 was 99.2% (95% CI: 95.7-100) specific with sera from 128 negative controls 
and 98.7% (95% CI: 93.1-100) sensitive with sera from 78 gHAT patients [28], which, at 0.05% 
prevalence, would yield a PPV of 6.0% (95% CI: 0.9 – 30.8%). At the same prevalence, the here 
described g-iELISA on plasma would yield a PPV of 9.2% (95% CI: 3.2-23.8%), which is still far from 
optimal. Interestingly, maximum PPV, was obtained when testing DBS instead of plasma (due to 
100% specificity). For large-scale surveillance, the easiest specimen to collect is DBS, which is used in 
other disease surveillance programmes. Active, village-based screening for gHAT by means of 
collecting DBS for remote testing in ELISA or other antibody detection tests has already been 
proposed a long time ago as an alternative to active screening by mobile teams [23, 30]. Its cost-
effectiveness is evaluated in an ongoing study in Côte d'Ivoire, Burkina Faso, Guinea and DRC 
(https://www.ditect-hat.eu/). More detailed analysis is required to assess the level of certainty the 
g-iELISA would provide in verifying whether the elimination of transmission goal has been reached 
using this collection framework. The benefits of other plausible sampling schemes for measurement 
of the elimination goal could be quantified using state-of-the-art Bayesian statistical frameworks 
[31], historical data and mechanistic modelling approaches. 
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DBS specimen are currently collected in gHAT sentinel sites established with the help of the WHO in 
15 endemic countries [32]. They are subsequently sent to the few reference laboratories where TL is 
performed, thus allowing detection of gHAT cases in non-endemic foci [33]. Replacing TL by g-iELISA 
opens perspectives to set up a larger network of sentinel sites in the most remote foci of an endemic 
country linked to national or regional laboratories equipped for ELISA testing. This will cut 
operational costs and the delay between sampling and test result, which, for obvious reasons, is 
beneficial to the national or international programmes involved in gHAT elimination. Operational 
costs will further be reduced by the lower price of g-iELISA (3 €/test) compared to TL (5-7 €/test).  
Results obtained with the current version of the g-iELISA are promising, in particular since diagnostic 
accuracy was similar on samples originating from West and Central Africa. However, further 
investigations may be considered to overcome inherent disadvantages. For instance, accelerated 
stability testing showed the limited stability of the LiTat 1.3 antigen at 22°C and higher, thus 
necessitating storage and long-distance transport of the kit between 2-8°C. Furthermore, the need 
to cut out 8 x 6 mm diameter discs from each DBS prior to actually testing the eluted fraction, puts a 
limit on the number of samples that can be tested simultaneously by one lab technician. As an 
alternative, small blood volumes could be dried in the wells of a microfiltration plate that contains a 
suitable absorbing filter pad from which the test sample can be eluted via vacuum or centrifugation. 
Also, replacing the native antigens, which are produced in laboratory rodents, by recombinant 
antigens or peptides, would be a major achievement in the context of the 3Rs (Replacement, 
Reduction and Refinement of animals in research). In previous studies, we developed alternative 
diagnostic antigens, derived from the VSGs LiTat 1.3 and LiTat 1.5, in the form of synthetic peptides 
and recombinant antigens produced in Pichia pastoris and Leishmania tarentolae [34-37]. 
Unfortunately, none of these antigens reacted with the highly VAT-specific monoclonal antibodies 
currently used in the g-iELISA, thus necessitating the development of new monoclonal antibodies 
before an inhibition ELISA with these alternative antigens can be constructed. 
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The present study has a limitation that makes it difficult to compare the sensitivity and specificity of 
the g-iELISA with those reported in other studies on gHAT serodiagnostics. Most gHAT patients, from 
which the plasma samples were collected, were screened with CATT/T.b. gambiense before 
undergoing parasitological confirmation. In addition, endemic controls were generally defined as 
negative in CATT/T.b. gambiense. Thus, we observed TL negatives among the gHAT patients and TL 
positives among the controls. However, since the aim was to develop an ELISA with similar 
characteristics as TL, we used the latter as a reference test and not the positive or negative status in 
parasitological examination. To assess its clinical accuracy and robustness, the g-iELISA should be 
evaluated under conditions prevailing in reference laboratories in the endemic countries.  
In conclusion, the diagnostic sensitivity and specificity of this prototype g-iELISA comply with the 
minimum requirements set in the TPP, in particular when testing with DBS. As such, the test might 
largely replace the TL for monitoring the gHAT elimination progress and for post-elimination 
surveillance. The RUO ELISA kit is available for evaluation in reference laboratories in gHAT endemic 
countries. 
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Table 1: Diagnostic parameters obtained in g-iELISA on plasma with TL as reference test. TP = true 
positive, FN = false negative, TN = true negative, FP = false positive, CI = confidence interval. 
  
 
TP FN TN FP Sensitivity % 95% CI Specificity % 95% CI 
All countries 724 15 616 3 98.0 96.7-98.9 99.5 98.6-99.9 
DRC 529 13 567 3 97.6 95.9-98.7 99.5 98.5-99.9 
Guinea 89 0 30 0 100.0 95.9-100.0 100.0 88.4-100.0 
Chad 75 2 19 0 97.4 90.9-99.7 100.0 82.3-100.0 
Uganda 31 0 - - 100.0 88.8-100.0 - - 
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Table 2: Diagnostic parameters obtained in g-iELISA with DBS and the corresponding plasma 
samples. TL is used as reference test. TP = true positive, FN = false negative, TN = true negative, FP = 
false positive, CI = confidence interval. 
  
 
TP FN TN FP Sensitivity % 95% CI Specificity % 95% CI 
Plasma 90 5 37 0 94.7 88.1-98.3 100 90.5-100.0 
DBS 88 7 37 0 92.6 85.4-97.0 100 90.5-100.0 
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 Antigen LiTat 1.3 Antigen LiTat 1.5 
 Sample 1 Sample 2 Sample 1 Sample 2 
Average % inhibition 58.8 78.9 56.0 78.5 
Standard deviation 3.4 2.1 2.8 1.2 
% coefficient variation 5.8 2.6 5.0 1.6 
 
Table 3: Repeatability of results obtained in the g-iELISA by testing 2 trypanolysis-positive samples 
20x in the same run. 
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Antigen LiTat 1.3 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
Mean % inhibition 60.6 47.9 66.7 43.0 0.2 55.2 
Standard deviation 3.5 6.1 5.5 8.1 4.0 7.2 
% coefficient variation 5.7 12.8 8.2 18.9 5.7 13.1 
Antigen LiTat 1.5 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
Mean % inhibition 58.2 79.1 80.8 37.5 37.7 70.4 
Standard deviation 3.8 2.1 1.4 6.4 5.3 3.2 
% coefficient variation 6.5 2.7 1.7 17.2 14.0 4.5 
 
Table 4: Reproducibility of results obtained in the g-iELISA by testing 6 trypanolysis-positive samples 
in 4 different runs. 
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Figure Legends 
Figure 1: Frequency plots of % inhibition results obtained with 87 TL-positive and 275 TL-negative 
samples in the g-iELISA with LiTat 1.3 and LiTat 1.5 antigen. Dashed lines indicate the cut-off value 
range with highest Youden index. 
 
 
Figure 2: Accelerated stability results. Four trypanolysis-positive and 2 trypanolysis-negative samples 
were tested with g-ELISA kits after 7, 14, 21, 28, 42 and 56 days storage at 22°C and 37°C, and after 7 
and 14 days storage at 45°C.  
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Figure 2 
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